12.09.2016 Evonik Industries AG  DE000EVNK013

DGAP-News: Evonik Industries AG: Evonik reduces production capacity for superabsorbents


 
DGAP-News: Evonik Industries AG / Key word(s): Miscellaneous Evonik Industries AG: Evonik reduces production capacity for superabsorbents 12.09.2016 / 11:30 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Evonik reduces production capacity for superabsorbents Essen. Evonik recently reduced production capacity for superabsorbents by 40,000 metric tons to 530,000 meric tons per year. The production lines concerned are those at the Garyville and Greensboro (North Carolina, USA) sites, two of Evonik's five superabsorbents production sites worldwide. "With this measure we're adapting to demand trends. We plan to take the opportunity to bring capacity to the technological state of the art and to start up the lines again in 1 - 2 years," says Norbert Westerholt, head of the Baby Care Business Line at Evonik. Evonik is pursuing the goal of remaining a reliable, competitive, and innovative partner of superabsorbents customers over the long term. As one of the leading suppliers of superabsorbents, Evonik is established as a reliable, innovative and long-term partner in the superabsorbents industry. Company information Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik's corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms. Evonik is active in over 100 countries around the world. In fiscal 2015 more than 33,500 employees generated sales of around EUR13.5 billion and an operating profit (adjusted EBITDA) of about EUR2.47 billion. About Nutrition & Care The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 7,000 employees, and generated sales of around EUR4.9 billion in 2015 Disclaimer In so far as forecasts or expectations are expressed in this Investor Relations News or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release. Contact: Tim Lange Head of Investor Relations +49 201 177-3150 [email protected] Evonik Industries AG Rellinghauser Straße 1-11 45128 Essen Germany Phone +49 201 177-01 Telefax +49 201 177-3475 www.evonik.com Supervisory Board Dr. Werner Müller, Chairman Executive Board Dr. Klaus Engel, Chairman Christian Kullmann, Deputy Chairman Dr. Ralph Sven Kaufmann Thomas Wessel Ute Wolf Registered office Essen Registered court Essen local court Commercial registry B 19474 VAT ID no. DE 811160003 --------------------------------------------------------------------------- 12.09.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: Evonik Industries AG Rellinghauser Straße 1-11 45128 Essen Germany Phone: +49 (0) 201 177-01 Fax: +49 (0) 201 177-3475 E-mail: [email protected] Internet: www.evonik.com ISIN: DE000EVNK013, XS0911405784 WKN: EVNK01, A1TM7T Indices: MDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Luxemburg End of News DGAP News Service --------------------------------------------------------------------------- 500689 12.09.2016


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 14.419,00 15.024,00 13.108,00 12.199,00 14.955,00 18.488,00 15.267,00
EBITDA1,2 2.357,00 2.150,00 2.153,00 1.837,00 2.246,00 2.510,00 1.598,00
EBITDA-Marge3 16,35 14,31 16,43 15,06 15,02 13,58
EBIT1,4 1.229,00 1.367,00 1.080,00 819,00 1.173,00 942,00 -243,00
EBIT-Marge5 8,52 9,10 8,24 6,71 7,84 5,10 -1,59
Jahresüberschuss1 734,00 954,00 2.127,00 479,00 767,00 555,00 -452,00
Netto-Marge6 5,09 6,35 16,23 3,93 5,13 3,00 -2,96
Cashflow1,7 1.551,00 1.704,00 1.321,00 1.727,00 1.815,00 1.650,00 1.594,00
Ergebnis je Aktie8 1,54 2,00 4,52 1,00 1,60 1,16 -1,00
Dividende8 1,15 1,15 1,15 1,15 1,17 1,17 1,15
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: KPMG

INVESTOR-INFORMATIONEN
©boersengefluester.de
Evonik Industries
WKN Kurs in € Einschätzung Börsenwert in Mio. €
EVNK01 19,270 Halten 8.979,82
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
14,82 15,91 0,94 11,93
KBV KCV KUV EV/EBITDA
1,07 5,63 0,59 7,69
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
1,17 1,17 6,07 04.06.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
08.05.2024 01.08.2024 06.11.2024 04.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
8,86% 8,86% 4,16% -2,55%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Evonik Industries AG  ISIN: DE000EVNK013 können Sie bei EQS abrufen


Chemie , EVNK01 , EVK , XETR:EVK